The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

The EMA's human medicines committee has recommended approval for Bavarian Nordic's chikungunya vaccine, which is shaping up to be the first alternative to a rival shot from Valneva. The CHIKV VLP ...

Rival developer Bavarian Nordic recently filed its single-dose CHIKV VLP vaccine candidate for chikungunya in the EU and US, seeking approval for individuals aged 12 and over. Bain Capital has ...

Accordingly, the single-shot vaccine branded as Ixchiq will be indicated in the U.K. for those 18 years and older to prevent chikungunya, a mosquito-borne disease caused by the chikungunya virus.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...

Shares of Valneva (VALN), a specialty vaccine company closed up over $ ... in the United Kingdom “for the world’s first and only chikungunya vaccine, IXCHIQ.” Published first on TheFly ...

The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus or CHIKV in individuals 18 years of age and older. The UK approval marks the ...